Dianthus Therapeutics, Inc.
DNTH
$20.62
$0.653.26%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | -95.08% | -55.64% | -56.89% | -63.65% | -52.95% |
Total Depreciation and Amortization | 16.06% | 45.18% | 124.10% | 69.33% | 141.50% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 355.52% | 302.23% | 377.83% | 177.73% | 61.95% |
Change in Net Operating Assets | -107.22% | -120.13% | -108.84% | 219.74% | 394.13% |
Cash from Operations | -112.09% | -84.86% | -62.27% | -21.99% | -26.80% |
Capital Expenditure | 4.55% | 34.88% | -18.10% | 5.88% | 20.86% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -1,507.98% | -1,803.99% | -21.91% | 92.16% | 134.12% |
Cash from Investing | -1,516.15% | -1,818.41% | -21.89% | 91.88% | 133.86% |
Total Debt Issued | -- | -100.00% | -100.00% | -100.00% | -- |
Total Debt Repaid | -- | 100.00% | 100.00% | 100.00% | -- |
Issuance of Common Stock | 5,405,660.00% | 4,612,140.00% | -- | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -110.98% | -114.11% | -- | 3,744.61% | 4,118.32% |
Cash from Financing | 91.37% | 52.47% | -- | 263.50% | 38.17% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -193.50% | -202.53% | 632.97% | 1,361.63% | 1,402.07% |